Not all individuals with CLL demand therapy. Despite all modern developments, the iwCLL continue to endorses watchful observation for sufferers with asymptomatic sickness.86 This advice is predicated on at least two randomized trials comparing observation to either chlorambucil monotherapy or fludarabine, cyclophosphamide and rituximab (FCR).103,10